VEGFA and neoplasm: Indeed, we and othershave demonstrated that VEGF pathway inhibitors can elicit both tumor- and host-mediated reactions totherapy that can offset (reduce) benefits, or even facilitate, early-stage metastatic disease incertain instances (Ebos et al, 2009;Paez-Ribes et al, 2009).